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A multi-institutional phase II trial was conducted to evaluate the efficacy and toxicity of combination chemotherapy consisting of
gemcitabine and UFT, which is composed of tegafur and uracil, for non-small-cell lung cancer (NSCLC) patients. Patients with
advanced NSCLC received an oral administration of UFT (tegafur 200mgm
 2) b.i.d. from days 1 to 14 and intravenous injection of
gemcitabine 900mgm
 2 on days 8 and 15. This treatment was repeated every 4 weeks. A total of 44 patients were enrolled into this
trial. The median age of all patients was 74 years, with 23 patients younger than 75 years and 21 patients with 75 years of age or
older. A total of 18 patients (41%) achieved a partial response. The median survival time was 13.2 months and the 1-year survival rate
was 59%. The most common grade 3–4 toxicity was neutropenia (57%). The frequency of grade 3 nonhaematologic toxicities was
less than 5%. In addition, no significant difference in the response, survival or toxicities was observed between the patients younger
than and those older than 75 years of age. This combination chemotherapy demonstrated a promising effectiveness and acceptable
toxicity in patients with advanced NSCLC, even in patients older than 75 years.
British Journal of Cancer (2005) 93, 770–773. doi:10.1038/sj.bjc.6602781 www.bjcancer.com
Published online 20 September 2005
& 2005 Cancer Research UK
Keywords: uracil–tegafur; UFT; gemcitabine; NSCLC; elderly
                                                    
UFT is an oral anticancer agent composed of tegafur and uracil at a
1:4 fixed molar ratio (Fujii et al, 1979). Although the clinical
effectiveness of the single agent against advanced non-small-cell
lung cancer (NSCLC) has not been evaluated in adequate sample
size (Keicho et al, 1986), a recent randomised phase III trial in 984
patients with completely resected stage I adenocarcinoma demon-
strated that postoperative adjuvant chemotherapy with UFT
significantly prolonged the survival of patients in comparison to
observation alone (Kato et al, 2004). The combination chemotherapy
of UFT plus cisplatin has also been reported to be an effective
treatment for advanced NCSLC. The combination chemotherapy
consisting of a daily administration of UFT for 2 or 3 weeks and a
bolus injection of cisplatin at the mid-cycle of the administration of
UFT yields a response rate of 29–38%, and a median survival time
of 10–13 months (Ichinose et al, 1995, 2000; Saito et al,2 0 0 1 ) .
Gemcitabine is an active anticancer agent for the treatment of
NSCLC. The objective response rates of patients with advanced
NCSLC treated with gemcitabine alone and the combination
chemotherapy of platinum plus gemcitabine range from 20 to 26%
and from 25 to 61%, respectively (Harper, 2003). A median
survival time of 8–16 months in patients treated with the
combination chemotherapy has been reported (Harper, 2003).
Both 5-FU generated from tegafur in UFT and gemcitabine are
antimetabolites but inhibit DNA synthesis via a different pathway.
The main mechanism of inhibiting DNA synthesis by 5-FU is due
to 5-FU-derived fluorodeoxy monophosphate binding to thymi-
dylate synthase (Madajewicz et al, 1984). The incorporation of
gemcitabine triphosphate, which is generated from the phosphory-
lation of gemcitabine by deoxycytidine kinase, into DNA is most
likely the major mechanism by which gemcitabine exerts its
cytotoxic action (Huang et al, 1991). Such different antitumour
mechanisms suggest a potential synergism between 5-FU and
gemcitabine. This potential synergism has been indeed observed in
in vitro studies using various cancer cell lines (Schulz et al, 1998;
Peters et al, 2000).
In our prior phase I trial, the combination chemotherapy of UFT
plus gemcitabine was found to be feasible (Seto et al, 2002). The
most appropriate schedule and dosing was 200mgm
 2 of UFT
b.i.d for 14 consecutive days with 900mgm
 2 gemcitabine on days
8 and 15. The main toxicity was haematologic. The overall
response rate was 33%, while the rate was 45% in the 13 patients
without any prior chemotherapy. With these backgrounds, we
conducted a phase II trial of combination chemotherapy using
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trial, we found the proportion of elderly, especially patients older
than 75 years of age, to be high. Therefore, the results of all
patients in the phase II trial and the differences between patients
younger than 75 years and those 75 years of age or older were
evaluated.
MATERIALS AND METHODS
Patient eligibility
The patients were eligible for this phase II trial if they had been
either cytologically or histologically confirmed to have NSCLC;
stage IIIB without any indications for radiotherapy or stage IV;
measurable disease; no prior chemotherapy; an Eastern Coopera-
tive Oncology Group (ECOG) performance status (PS) of 0, 1 or 2;
a projected life expectancy of at least 3 months. Other eligibility
criteria regarding organ functions were as follows: a leucocyte
count of 4000–12000l
 1; platelet count of 100000ml
 1 or greater;
haemoglobin level of 9gdl
 1 or greater; a serum bilirubin level less
than 1.5mgdl
 1; serum aspartate aminotransferase and alanine
aminotransferase levels of twice the upper limit or less; a serum
creatinine level of 1.5mgdl
 1 or less. For staging, all patients
underwent a computed tomography (CT) scan of the thorax,
including the upper abdomen, and either brain CT or magnetic
resonance images of the brain, and a radioisotopic bone scan were
performed for almost all patients.
Any patients who were pregnant or had concomitant serious
diseases, a concomitant malignancy, pleural effusion necessitating
treatment or symptomatic cerebral involvement were excluded
from the study. However, patients whose malignant pleural
effusion was controlled by intrapleural hypotonic cisplatin
treatment (Ichinose et al, 2003) were eligible. Written informed
consent was required from all patients and the protocol was
approved by the institutional ethics committee of each of the
participating institutions. On entrance to the study, the eligibility
of patients was checked via facsimile by the central administration
office of the Kyushu Yamaguchi Thoracic Oncology Group
(Fukuoka).
Treatment schedule
UFT (tegafur 400mgm
 2day
 1) in the form of a 100-mg capsule
(100mg of tegafur plus 224mg of uracil) was given orally in two
separate doses, before meals, from days 1 to 14. The dose was
rounded up or down to the nearest 100mg. Most patients received
UFT three capsules (tegafur 300mg and uracil 672mg) b.i.d.
Gemcitabine (900mgm
 2) was dissolved in 20ml of physical
saline and then diluted further with physical saline or 5% glucose
to a volume of 250ml. The gemcitabine solution was administered
by intravenous drip infusion over 30min on days 8 and 15. On the
day gemcitabine was administered, a complete blood count was
performed and the drug was administered only when the leucocyte
count was 2000ml
 1 or higher and the platelet count was 70000 or
higher ml
 1. If these requirements were not met, then drug
administration was postponed for a maximum of 4 days. The
treatment regimen was repeated every 4 weeks and at least two
cycles were administered unless disease progression or an
unacceptable toxicity occurred. A leucocyte count of 3000ml
 1 or
greater and the entry eligibility criteria regarding organ functions
had to be satisfied to start the next cycle. The doses of gemcitabine
were reduced to 800mgm
 2 either when grade 4 haematologic
toxicities occurred or when the administration of gemcitabine on
day 15 was skipped in a prior cycle. The doses were increased to
1000mgm
 2 if both nadirs of the leucocyte and platelet counts
were more than 3000 and 100000ml
 1, respectively, in a prior
cycle.
Evaluation of response and toxicity
All eligible patients who received any part of the treatment were
considered assessable for response and toxicity. The complete
blood count, and blood chemistry studies were repeated weekly.
The response was assessed based on the chest X-ray or CT scan
findings that initially had been used to define tumour extent.
The response was evaluated according to the criteria of the World
Health Organization (Miller et al, 1981). A central radiologic
review was performed to determine the eligibility of patients and
the response of treatment. Any adverse events were graded
according to the National Cancer Institute-Common Toxicity
Criteria (NCI-CTC) version 2.0.
Statistical analysis
The primary end point of this study was to determine the tumour
response rate produced with this treatment protocol. Based on the
assumption that a response rate of higher than 40% would warrant
a further investigation of this combination chemotherapy, and
that a rate of below 20% would make such an investigation
unnecessary, a sample size of 36 patients was required with an
alpha error of 0.05 and a beta error of 0.2. Therefore, the accrual of
40 patients was planned for a 2-year period since several ineligible
patients might be identified in the course of the study.
The overall survival of the eligible patients was defined as the
time from the start of the treatment until death from any cause and
it was estimated by the Kaplan–Meier method. Differences
between the proportions were evaluated by the chi-square test.
The data were considered to be significant when the P-value was
0.05 or less.
RESULTS
Patient characteristics
From July 2000 to September 2002, 44 patients were entered into
this phase II trial. Since no upper age limit for the eligibility
criteria was established, in contrast to other Japanese trials, many
elderly patients were included in this trial. The patient characteris-
tics classified by an age of less than 75 years of age or 75 years of
age and older are shown in Table 1. There were no statistically
significant differences in the proportions regarding gender,
performance status, stage, histology or previous treatment between
the two (o75 vs X75 years) groups. There were 33 patients who
were 70 years of age or older.
Treatment delivery
The median number of treatment cycles for all patients was three
as shown in Table 2. In all, 39 (89%) patients received at least
two cycles of the treatment. The reasons for terminating the
chemotherapy before the second treatment cycle were adverse
events in three patients, a progression of dementia in one and
patient refusal in one. Although the proportions of the cycles
administered between the two-age groups showed no significant
difference, 10 (48%) patients in the older age group received five or
more cycles of the treatment.
The administration of gemcitabine on day 15 was skipped in
10 (5%) of a total of 196 cycles. A dose decrease to 800mgm
 2 and
the increase to 1000mgm
 2 were reported in four and five
patients, respectively.
Adverse events
The main adverse events were haematologic toxicities as shown
in Table 3. Grade 3 and 4 neutropenia was reported in 57% of
the patients and grade 4 in 20%, while no grade 4 anemia or
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haematologic toxicities was 57% in the younger-age group and
62% in the older-age group. The frequency of grade 3 or greater
nonhaematologic toxicities was 5% or less. No grade 4 non-
haematologic toxicity was observed.
Response
Among the 44 patients, 18 patients showed a partial response
(41%; 95% confidence interval, 26–55%). There were 24 patients
(55%) with no change and two patients (5%) with progressive
disease. There were no differences in the response rate according
to age (o75 vs X75 years, 44 vs 38%), gender (male vs female, 46
vs 33%), stage (III vs IV, 42 vs 41%) and histology (adenocarci-
noma vs others, 44 vs 33%). Median duration of response was 6.9
months.
Survival
The overall median follow-up time for all patients was 38 months
(range from 23 to 50 months). As shown in Figure 1, the median
survival time of all 44 patients was 13.2 months, and the survival
rates at 1 and 2 years were 59% (95% confidence interval, 45–74%)
and 34% (95% confidence interval, 20–48%), respectively. There
were no statistically significant differences in survival between
the patients under 75 and those over 75 years (P¼0.4948). The
median survival time was 13.2 and 13.3 months, respectively.
DISCUSSION
Platinum-based combination chemotherapy is recommended for
the treatment of advanced NSCLC patients with a good perfor-
mance status (Pfister et al, 2004). However, the incidence of severe
adverse effects induced by this combination chemotherapy is
indeed more frequently observed in elderly patients than younger
patients even if the subjects have good performance status (Langer
et al, 2002). Therefore, a single agent such as vinorelbine, whose
effect on prolonging survival in advanced NSCLC with elderly has
been demonstrated in comparison to the best supportive care
(Anonymous, 1999), is sometimes selected to treat such patients
in practice. In addition, the combination of vinorelbine plus
gemcitabine has been reported to be not more effective than
single-agent vinorelbine or gemcitabine in the treatment of elderly
patients with advanced NSCLC (Gridelli et al, 2003).
Lung cancer is primarily a disease of the elderly. More than one
half of new diagnoses and more than two-thirds of annual deaths
occur in patients over 65 years (Havlik et al, 1994; Gridelli et al,
1997). Although the aim of the present study was not to develop a
treatment for only the elderly, the median age of the patients in
this study was 74 years and 48% of the patients were 75 years or
older. The reasons for this age distribution were thought to be
partly due to the followings: First, the subjects of almost all
previous clinical trials for chemotherapy against advanced NSCLC
conducted in Japan were limited to patients under 75 years of age.
Second, both UFT and gemcitabine were considered to be
relatively safe anticancer agents. Third, they could be administered
on an outpatient basis with no need for premedication and
prehydration.
Table 1 Patient characteristics
o75 years
(n¼23)
X75 years
(n¼21)
Total
(n¼44)
Age
Median (range) 70 (58–74) 78 (75–89) 74 (58–89)
Gender
Male/female 7/16 11/10 18/26
Performance status (ECOG)
0/1/2 8/13/2 8/13/0 16/26/2
Stage
III/IV 5/18 7/14 12/32
Histology
Adenoca/others 17/6 15/6 32/12
Previous treatment
None 11 11 22
HPT
a 68 1 4
Operation 5 2 7
Radiotherapy 1 0 1
aHypotonic cisplatin treatment. ECOG¼Eastern Cooperative Oncology Group.
Table 2 Treatment delivery
Cycle of treatment
o75 years
(n¼23)
X75 years
(n¼21)
Total
(n¼44)
1 23 (100%) 21(100%) 44 (100%)
2 21 (91%) 18 (86%) 39 (89%)
3 12 (52%) 14 (67%) 26 (59%)
4 9 (39%) 11 (52%) 20 (45%)
X5 6 (26%) 10 (48%) 16 (36%)
No. of cycles
Median 3 4 3
Range 1–18 1–16 1–18
Table 3 Haematologic and nonhaematologic toxicities (n¼44)
Grade
Toxicity 1 2 3 4 Frequency of Grade 3 or 4 (%)
Leukopenia 4 19 13 1 32
Neutropenia 5 8 16 9 57
Anemia 22 13 4 0 9
Thrombocytopenia 15 9 8 0 18
GOT 8 1 0 0
GPT 10 1 0 0
Creatinine 1 0 0 0
Anorexia 4 1 2 0 5
Vomiting 2 2 0 0
Diarrhoea 0 1 2 0 5
AIP 0 0 1 0 2
Febrile neutropenia 0 0 1 0 2
GOT¼glutamic oxaloacetic transaminase; GPT¼glutamic pyruvic transaminase;
ALP¼alkaline phosphatase.
0
20
40
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100
01 2 24 36 48
All patients (n=44), MST=13.2 months
Months
Percent survival
Figure 1 Overall survival. Each tick represents a patient who is alive.
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gemcitabine was 41%. In a phase I trial of this combination
chemotherapy, the response rate of patients without prior chemo-
therapy was also reported to be 45% (Seto et al, 2002). This high
antitumour effect may lend support to the sequence of administra-
tion of UFT and gemcitabine. In fact, an in vitro study has shown the
sequence-dependent antitumour effects of the combination of
5-FU and gemcitabine to be seen with a maximum effect when 5-
FU preceded gemcitabine (Rauchwerger et al,2 0 0 0 ) .S i n c et h e5 - F U
concentration in blood reaches a steady state 5 days after the start
of UFT administration (Ho et al, 1998), the administration of
gemcitabine on days 8 and 15 is considered to be most appropriate.
Since the recent randomised trial demonstrated that gemcita-
bine plus carboplatin produced a significantly higher response rate
and survival rate than gemcitabine alone in advanced NSCLC
patients including a substantial proportion of elderly patients
(37% of patients 470 years old), the combination chemotherapy
using gemcitabine and carboplatin (Sederholm, 2002) may also be
considered to be a suitable chemotherapy regimen for the
treatment of elderly patients. The response rate and median
survival time in the combination chemotherapy group has been
reported to be 30% and 10 months, respectively. Grade 3 or 4
nonhaematologic toxicity was observed in 26% of the patients,
while grade 3 and 4 thrombocytopenia was reported in 24% each of
patients, respectively. A toxicity profile in the elderly has not yet
been reported.
In the present phase II trial of 44 patients with a median age
of 74 years, including 21 patients who were 75 years or older,
the response rate was 41% and the median survival time was
13.4 months. These observations suggest that this combination
chemotherapy is also worthy of further investigation for the
treatment of all NSCLC patients including the elderly. In addition,
it should be confirmed whether or not this combination regimen is
equally effective in ethnic groups other than Japanese.
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